作者
Emilio Perucca,Jacqueline A. French,Ghaieb Aljandeel,Simona Balestrini,Patricia Braga,Jorge G. Burneo,Augustina Charway‐Felli,J. Helen Cross,Aristea S. Galanopoulou,Suman Jain,Yuwu Jiang,Reetta Kälviäinen,Shih Hui Lim,Kimford J. Meador,Zarine Mogal,Rima Nabbout,Francesca Sofia,Ernest Somerville,Michael R. Sperling,Chahnez Triki,Eugen Trinka,Matthew C. Walker,Samuel Wiebe,Jo M. Wilmshurst,Elaine Wirrell,Elza Márcia Targas Yacubian,Jaideep Kapur
摘要
Abstract A variety of terms, such as “antiepileptic,” “anticonvulsant,” and “antiseizure” have been historically applied to medications for the treatment of seizure disorders. Terminology is important because using terms that do not accurately reflect the action of specific treatments may result in a misunderstanding of their effects and inappropriate use. The present International League Against Epilepsy (ILAE) position paper used a Delphi approach to develop recommendations on English‐language terminology applicable to pharmacological agents currently approved for treating seizure disorders. There was consensus that these medications should be collectively named “antiseizure medications”. This term accurately reflects their primarily symptomatic effect against seizures and reduces the possibility of health care practitioners, patients, or caregivers having undue expectations or an incorrect understanding of the real action of these medications. The term “antiseizure” to describe these agents does not exclude the possibility of beneficial effects on the course of the disease and comorbidities that result from the downstream effects of seizures, whenever these beneficial effects can be explained solely by the suppression of seizure activity. It is acknowledged that other treatments, mostly under development, can exert direct favorable actions on the underlying disease or its progression, by having “antiepileptogenic” or “disease‐modifying” effects. A more‐refined terminology to describe precisely these actions needs to be developed.